US02043Q1076
© BusinessWire
11.12.2025
ALNY
LISTED
NASDAQ
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
News Preview
Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% Convertible Senior Notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggre...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2025
ALNY
LISTED
NASDAQ
Alnylam Pharmaceuticals Announces Changes to Board of Directors
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam’s Board, stepped down effective December...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ALNY
LISTED
NASDAQ
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneu...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
04.11.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:
UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida
Jefferies Global Healthcare Conference o...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
30.10.2025
ALNY
LISTED
NASDAQ
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights.
“Alnylam’s impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open.
Management will provide an update on the Company and discuss third quarter 2025 results a...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
ALNY
LISTED
NASDAQ
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), a global Phase 3 cardiovascular outcomes trial (CVOT) designed to evaluate the potential of zilebesiran, an investigational biannual subcuta...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
ALNY
LISTED
NASDAQ
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
News Preview
Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ALNY
LISTED
NASDAQ
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
News Preview
Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the S...
Themefolio
Profiler
Peergroup
© BusinessWire
31.08.2025
ALNY
LISTED
NASDAQ
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2025
ALNY
LISTED
NASDAQ
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program,...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
ALNY
LISTED
NASDAQ
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights.
“Our results during the second quarter highlight Alnylam’s unique ability to quickly deliver and enable commercial access to inn...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
17.07.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open.
Management will provide an update on the Company and discuss second quarter 2025 results as well...
Themefolio
Profiler
Peergroup
© PR Newswire
02.07.2025
ALNY
LISTED
NASDAQ
OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients
News Preview
OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1
MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via su...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
ALNY
LISTED
NASDAQ
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with car...
Themefolio
Profiler
Peergroup
© BusinessWire
09.06.2025
ALNY
LISTED
NASDAQ
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therape...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET.
A live audio webcast of the presentation will be available on the Investors section of the Compan...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
ALNY
LISTED
NASDAQ
Alnylam Issues 2024 Corporate Responsibility Report
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This y...
Themefolio
Profiler
Peergroup
© BusinessWire
17.05.2025
ALNY
LISTED
NASDAQ
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Soc...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
ALNY
LISTED
NASDAQ
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade,...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET).
A live audio webcast of the presentation will be available on the Investors section of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
ALNY
LISTED
NASDAQ
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights.
“2025 is off to a remarkable start, having ended the first quarter with U.S. regulatory approval of AMVUTTRA for ATTR-CM. This im...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
ALNY
LISTED
NASDAQ
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hered...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open.
Management will provide an update on the Company and discuss first quarter 2025 results as well as...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET.
A live audio webcast of the presentation will be available on the Investors section of the Company’s...
Themefolio
Profiler
Peergroup
© BusinessWire
29.03.2025
ALNY
LISTED
NASDAQ
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today’s patients. Data we...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
ALNY
LISTED
NASDAQ
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
ALNY
LISTED
NASDAQ
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloid...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET.
A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnyla...
Themefolio
Profiler
Peergroup
© BusinessWire
05.03.2025
ALNY
LISTED
NASDAQ
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company’s Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnyl...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
ALNY
LISTED
NASDAQ
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D progress and platform innovation, including updates on multiple near- and mid-stage potentially transformative therapies that represent bloc...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
ALNY
LISTED
NASDAQ
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and reviewed recent business highlights.
“2024 was another year of impressive execution for Alnylam, generating product revenues of over $1.6 billion,...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open.
Management will provide an update on the Company and discuss fourth quarter and...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2025
ALNY
LISTED
NASDAQ
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In addition, the Company provided 2025 net product revenue, non-GAAP operating income profitability, and pipeline goals gui...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City.
A live audio webcast of the presentation will...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
ALNY
LISTED
NASDAQ
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyop...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2024
ALNY
LISTED
NASDAQ
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT (11:45 ET) at the Terranea Resort in Ranchos Palos Verdes, CA
Jefferies London Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
ALNY
LISTED
NASDAQ
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights.
“Alnylam continued to deliver robust results commercially and clinically in the third quarter. We achieved 34% year-over-year...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
ALNY
LISTED
NASDAQ
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA) Scientific Sessions 2024, November 16–18, 2024.
Data presentations for the Company’s flagship T...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
ALNY
LISTED
NASDAQ
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2024 on Thursday, October 31, 2024, before the U.S. financial markets open.
Management will provide an update on the Company and discuss third quarter 2024 results as...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
ALNY
LISTED
NASDAQ
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is th...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2024
ALNY
LISTED
NASDAQ
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Sess...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ALNY
LISTED
NASDAQ
Alnylam to Webcast TTR Investor Day
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, October 9, 2024 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the ev...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2024
ALNY
LISTED
NASDAQ
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
The data were presented today in a Hot Line session at the Eur...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 9:30 am ET in Boston
Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday,...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
